SCHEMBL7119129

SCHEMBL7119129

c1ccc(-c2cnc(Nc3cccc(-n4ccnc4)c3)s2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 11/20 0.59
ABL1 P00519 2/20 0.54
PDGFRB P09619 2/20 0.54
BCR P11274 1/20 0.54
SRC P12931 1/20 0.54
PDGFRA P16234 1/20 0.54
PRKCA P17252 1/20 0.54
PRKCD Q05655 1/20 0.54
OTUD7B Q6GQQ9 1/20 0.47
CYP3A4 P08684 1/20 0.46
NAMPT P43490 1/20 0.45
MEN1 O00255 1/20 0.45
ALOX15 P16050 1/20 0.45
TSHR P16473 1/20 0.45
KMT2A Q03164 1/20 0.45
MAOA P21397 1/20 0.45
MAOB P27338 1/20 0.45
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC1 Q13547 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21362368 0.79 CYP3A4 (0.62) ABL1PDGFRBBCRSRCPDGFRA
SCHEMBL7117380 0.78 ALOX5 (0.58) ABL1PDGFRBBCRSRCPDGFRA
SCHEMBL3651635 0.76 KDR (1.00) KDRNAMPT
SCHEMBL7119144 0.76 KDR (0.58) KDRABL1PDGFRBCHEK1
SCHEMBL7130668 0.76 ABL1 (0.53) ABL1PDGFRBBCRSRCPDGFRA
SCHEMBL28512889 0.76 ABL1 (0.53) ABL1PDGFRBBCRSRCPDGFRA
SCHEMBL31440677 0.76 ABL1 (0.53) ABL1PDGFRBBCRSRCPDGFRA
SCHEMBL8592858 0.76 ABL1 (0.67) ABL1PDGFRBBCRSRCPDGFRA
SCHEMBL6330184 0.74 KDR (1.00) KDRABL1PDGFRBMEN1KMT2A
SCHEMBL19031368 0.74 IDO1 (0.48) ABL1PDGFRBBCRSRCPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176454-A1 N-coating heterocyclic compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-09-18 US claimed
US-20030176454-A1 N-coating heterocyclic compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176454-A1 N-coating heterocyclic compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 KDR 1404/4885ABL1 212/4885PDGFRB 2353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.